What shoulder care may cost you

Insurance often helps with basic shoulder care

Many plans help pay for an exam, an X-ray, physical therapy, medicine for swelling, and sometimes a cortisone shot. Ask whether the clinic is on your plan’s approved list and what part of the bill you’ll owe. Don’t assume familiar care costs the same at every office.

Your health plan gives the final answer.

A shoulder injection may be covered or paid in cash

A cortisone shot and PRP aren’t billed alike. The full name for PRP is platelet-rich plasma. Blood drawn at the clinic goes into a machine that spins it, allowing one portion with extra platelets to be saved. Platelets help blood clot. Shoulder PRP is generally paid in cash, so find out if the quoted amount covers the exam and later visits.

One quote may not cover everything.

Medicare usually does not cover shoulder PRP

Medicare’s national rule covers PRP for certain long-lasting wounds, not usual shoulder care, and other plans may follow that rule. You’ll still need to check your own plan. Ask if the clinic will send any part of the bill to insurance. If it won’t, get the cash terms before booking.

Coverage and usefulness are two different questions.

No single Glendale price fits every visit

Clinic charges can change, and two sore shoulders may not need the same care. Studies compare cost with relief, but they don’t list a dependable Glendale charge. The clinic’s written quote is the useful number. It should state what is included and what could cost more later.

Clear terms now can prevent a surprise bill.

A written quote shows the full cash charge

Before paying a deposit or setting aside a day for care, ask whether the total covers blood preparation, an ultrasound used to aim the treatment, and a return visit. If the answer changes during the call, request the final terms in writing. You’re entitled to know what you’re buying.

There’s no need to rush a cash choice.

A few clear questions can settle the price

Tell the clinic what your shoulder can’t do and which care you’ve already tried. Ask what the exam may show, what the full charge includes, and whether the clinic will bill your insurance. You’ll also want to know whether you must pay the entire amount and what any later visit costs.

Plain answers make prices easier to compare.

Sources

1. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development study. There is no Medicare national coverage for PRP in shoulder osteoarthritis or rotator cuff disease, which is why these injections are billed to the patient directly.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

2. A meta-analysis with a formal cost-effectiveness analysis found PRP did not reduce retear risk across all tear sizes (RR 0.87, 95% CI 0.67-1.12) but did for small and medium tears under 3 cm (RR 0.60, 0.37-0.97; number needed to treat 14). At an incremental cost-effectiveness ratio of US$127,893 per quality-adjusted life year, the authors concluded PRP was NOT cost-effective even where it worked.

   Vavken P, et al. — Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective.. Am J Sports Med, 2015. DOI: 10.1177/0363546515572777.

3. In January 2025 federal court orders permanently BANNED the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy and imposed $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic charged up to $5,000 per injection, almost entirely to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

4. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. A 2025 systematic review of 1,125 patients receiving intra-articular injections for glenohumeral osteoarthritis reported a 7.2% overall complication rate and a 3.2% rate of proceeding to surgery. Hyaluronic acid showed consistent though modest benefit, while the evidence for ORTHOBIOLOGICS (PRP, bone marrow aspirate concentrate, mesenchymal stem cells) 'remains limited', mainly because of heterogeneity in design, outcomes and patient characteristics.

   Migliorini F, et al. — Intra-articular injections for shoulder arthritis in adults: a systematic review.. Eur J Med Res, 2025. DOI: 10.1186/s40001-025-03423-4.

6. A 2026 meta-analysis of 21 studies (1,279 patients) found leukocyte-poor PRP augmentation at rotator cuff repair reduced structural retear risk (overall RR 0.74, 95% CI 0.55-0.99), with the benefit clearest in medium-sized tears (RR 0.68). Patient-reported outcomes did NOT improve consistently, publication-bias diagnostics indicated small-study effects (Egger p=0.017), and trim-and-fill adjustment moved the estimate to a non-significant RR 0.91 (0.69-1.19).

   Dunivan Q, et al. — Leukocyte-poor platelet-rich plasma reduces retear risk after arthroscopic rotator cuff repair: a meta-analysis with mechanistic and economic evaluation.. J Shoulder Elbow Surg, 2026. DOI: 10.1016/j.jse.2026.02.018.